SPRY
NASDAQ · Biotechnology
Ars Pharmaceuticals Inc
$8.56
+0.30 (+3.63%)
Financial Highlights (FY 2026)
Revenue
89.26M
Net Income
-181,439,135
Gross Margin
76.7%
Profit Margin
-203.3%
Rev Growth
+299.7%
D/E Ratio
0.84
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 76.7% | 61.2% | 61.2% | 61.2% |
| Operating Margin | -212.9% | 12.9% | 15.2% | 14.7% |
| Profit Margin | -203.3% | 9.9% | 12.8% | 10.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 89.26M | 357.40M | 350.63M | 398.05M |
| Gross Profit | 68.48M | 218.64M | 214.50M | 243.51M |
| Operating Income | -190,059,137 | 46.04M | 53.12M | 58.40M |
| Net Income | -181,439,135 | 35.24M | 44.72M | 41.86M |
| Gross Margin | 76.7% | 61.2% | 61.2% | 61.2% |
| Operating Margin | -212.9% | 12.9% | 15.2% | 14.7% |
| Profit Margin | -203.3% | 9.9% | 12.8% | 10.5% |
| Rev Growth | +299.7% | +16.3% | -1.3% | +6.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 204.45M | 228.52M | 266.70M | 231.00M |
| Total Equity | 242.39M | 545.19M | 556.64M | 584.56M |
| D/E Ratio | 0.84 | 0.42 | 0.48 | 0.40 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -177,920,809 | 65.64M | 71.27M | 76.87M |
| Free Cash Flow | — | 46.75M | 30.69M | 51.61M |